Spero Therapeutics, Inc. (NASDAQ:SPRO – Get Free Report) Director Ankit Mahadevia sold 69,219 shares of the business’s stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $0.78, for a total value of $53,990.82. Following the transaction, the director now owns 689,866 shares of the company’s stock, valued at approximately $538,095.48. The trade was a 9.12 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
Spero Therapeutics Trading Down 1.6 %
Shares of Spero Therapeutics stock opened at $0.86 on Friday. The stock’s fifty day moving average price is $0.99 and its 200-day moving average price is $1.19. The firm has a market cap of $47.07 million, a P/E ratio of 12.33 and a beta of 0.61. Spero Therapeutics, Inc. has a 12 month low of $0.74 and a 12 month high of $1.89.
Analysts Set New Price Targets
SPRO has been the subject of several research analyst reports. TD Cowen reiterated a “hold” rating on shares of Spero Therapeutics in a research report on Monday, November 18th. Evercore ISI lowered shares of Spero Therapeutics from an “outperform” rating to an “in-line” rating and set a $5.00 price objective for the company. in a report on Friday, December 20th. Cantor Fitzgerald restated an “overweight” rating on shares of Spero Therapeutics in a research note on Friday, November 15th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $5.00 price target on shares of Spero Therapeutics in a research note on Thursday, January 30th.
About Spero Therapeutics
Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.
Further Reading
- Five stocks we like better than Spero Therapeutics
- Consumer Discretionary Stocks Explained
- Price Plunge in Roblox Presents Opportunity for Robust Gains
- 3 REITs to Buy and Hold for the Long Term
- Billions in Buybacks: 4 Stocks Rewarding Shareholders Now
- What Are Some of the Best Large-Cap Stocks to Buy?
- 3 Steel Stocks to Gain Strength as Tariffs Reshape the Market
Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.